Masumi George Asahi, DO
Ophthalmology · Santa Ana
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 7 years
- Graduated 2019
Offices
2 locations · Serve the People, Inc. · Retina Macula Institute
Hospitals listed: Uci Health-Orange. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Asahi’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Uci Health-OrangeOrange, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Chao Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.44 (3.82 to 7.06) · 2,934 cases, Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 82.98 (46.2 to 119.76) · 170 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.422, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.56, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.547, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.356, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.449, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 1,287 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Uci Health-Orange
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.44 (3.82 to 7.06) · 2,934 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 82.98 (46.2 to 119.76) · 170 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.422 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.56 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.547 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.356 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 1,287 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.25 to 1.87) · 2,297 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.67 to 1.13) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 59 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 104 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.3 · 331 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 416 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 330 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,269 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.33) · 8,263 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.37) · 8,703 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.95 (0.57 to 3.32) · 1,647 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.52 (1.33 to 3.71) · 2,756 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.15 (2.82 to 11.48) · 1,643 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.78 (2.24 to 7.33) · 1,680 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.61 to 3.36) · 871 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.28 (0 to 0.77) · 7,232 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 170 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.546 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 165 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 556 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 75.5 · 113 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0 · 391 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.4 · 436 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 556 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.1 to 6.6) · 846 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.8 (10 to 14) · 846 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.9 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 110 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.6 to 13.8) · 2,457 cases | No different | Jan 2022 – Dec 2024 |
What patients said (575 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$11,860
Medicare paid this office $11,860 for 82 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of eye fluid (vitreous) between lens and retina | 18 | $2,082 | $116 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Procedures year by year
| Procedure | 2023 | 2024 |
|---|---|---|
| Removal of eye fluid (vitreous) between lens and retina | – | 18 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
82 Original Medicare patients in 2024. Average age 73 · Women 54% · Also on Medicaid 32% · Health risk score 1.53. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 41% · Chronic kidney disease 34% · Coronary heart disease 30% · Depression 22% · Cancer 21% · Heart failure 20% · Stroke 17% · Atrial fibrillation 16%.
The office billed $125,292, Medicare allowed $15,055 and paid $11,860; for 112 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 82 | 112 | 73 | 1.53 | $125,292 | $11,860 |
| 2023 | 38 | 49 | 73 | 1.79 | $45,148 | $4,220 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Medicaid work
$83,734 in 2024
Medicaid paid $83,734 for 851 billed services this clinician did in 2024, up to 52 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 105 | $47,432 |
| Return visit (30+ min) | 355 | $24,062 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 356 | $10,073 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 35 | $2,166 |
| 2024 | 851 | 4 | 52 | $83,734 |
| 2023 | 613 | 4 | 56 | $64,220 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 109 | $42,263 |
| Return visit (30+ min) | 221 | $14,363 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 269 | $7,219 |
| Short return visit (20+ min) | 14 | $376 |
Drugs they prescribed that Part D paid
$56,840
Pharmacies billed $56,840 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 374) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
191 generic and 183 brand-name prescriptions · $56,840 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 11 | $15,362 | $1,397 |
| Cyclosporine | 14 | $9,742 | $696 |
| Prolensa | 19 | $8,772 | $462 |
| Bromfenac | 11 | $1,879 | $171 |
| Prednisolone Acetate | 55 | $1,858 | $34 |
See all 11 drugs
| Restasis | 11 | $15,362 | $1,397 |
| Cyclosporine | 14 | $9,742 | $696 |
| Prolensa | 19 | $8,772 | $462 |
| Bromfenac | 11 | $1,879 | $171 |
| Prednisolone Acetate | 55 | $1,858 | $34 |
| Timolol Maleate | 16 | $1,833 | $115 |
| Brimonidine Tartrate-Timolol | 11 | $730 | $66 |
| Dorzolamide-Timolol | 46 | $714 | $16 |
| Ketorolac Tromethamine | 39 | $710 | $18 |
| Latanoprost | 40 | $353 | $9 |
| Brimonidine | 25 | $302 | $12 |
Year by year
| 2024 | 374 | 123 | 0% (0) | 49% | $56,840 |
| 2023 | 293 | 134 | 0% (0) | 40% | $64,823 |
| 2022 | 220 | 108 | 0% (0) | 40% | $48,352 |
| 2021 | 440 | 150 | 0% (0) | 33% | $92,820 |
| 2020 | 131 | 58 | 0% (0) | 44% | $23,884 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Restasis | 11 | $14,868 | $1,352 |
| Rhopressa | 14 | $8,118 | $580 |
| Travoprost | 14 | $5,554 | $397 |
| Latanoprost | 50 | $1,536 | $31 |
| Prednisolone Acetate | 33 | $1,230 | $37 |
| Dorzolamide-Timolol | 34 | $1,077 | $32 |
| Timolol Maleate | 22 | $946 | $43 |
| Ketorolac Tromethamine | 18 | $406 | $23 |
| Brimonidine | 17 | $403 | $24 |
2022: 6 drugs
| Travoprost | 11 | $4,556 | $414 |
| Latanoprost | 46 | $1,616 | $35 |
| Prednisolone Acetate | 28 | $1,610 | $57 |
| Dorzolamide-Timolol | 12 | $803 | $67 |
| Ketorolac Tromethamine | 17 | $758 | $45 |
| Timolol Maleate | 17 | $606 | $36 |
2021: 11 drugs
| Restasis | 14 | $15,427 | $1,102 |
| Combigan | 24 | $13,018 | $542 |
| Travoprost | 31 | $11,915 | $384 |
| Alphagan P | 12 | $6,176 | $515 |
| Brimonidine | 26 | $3,944 | $152 |
| Latanoprost | 108 | $3,515 | $33 |
| Timolol Maleate | 37 | $1,843 | $50 |
| Dorzolamide-Timolol | 27 | $1,706 | $63 |
| Dorzolamide | 26 | $1,240 | $48 |
| Prednisolone Acetate | 25 | $1,138 | $46 |
| Erythromycin | 15 | $238 | $16 |
2020: 2 drugs
| Latanoprost | 23 | $1,036 | $45 |
| Prednisolone Acetate | 22 | $971 | $44 |
Money from drug and device companies
$755 in 2025
| 2025 | 7 | 18 | None | $755 |
| 2024 | 8 | 19 | None | $1,337 |
| 2023 | 7 | 11 | None | $371 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Eylea Hd | $188 | 4 payments
|
| Abbvie | Ozurdex | $188 | 4 payments
|
| Astellas Pharma US | Izervay | $157 | 6 payments
|
| Astellas Pharma Global Development | Izervay | $117 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $46 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $33 | 1 payment
|
See all 18 published payments
| ANI Pharmaceuticals | Meals · 2025-12-08 | Iluvien | $26 |
| Astellas Pharma US | Meals · 2025-11-25 | Izervay | $22 |
| Astellas Pharma US | Meals · 2025-11-20 | Izervay | $13 |
| Apellis Pharmaceuticals | Meals · 2025-10-29 | Syfovre | $33 |
| Abbvie | Meals · 2025-10-13 | Ozurdex | $22 |
| Astellas Pharma US | Meals · 2025-10-13 | Izervay | $11 |
| Regeneron Healthcare Solutions | Meals · 2025-09-17 | Eylea Hd | $10 |
| Regeneron Healthcare Solutions | Meals · 2025-09-17 | Eylea Hd | $38 |
| Astellas Pharma US | Meals · 2025-08-01 | Izervay | $75 |
| Abbvie | Meals · 2025-06-26 | Ozurdex | $16 |
| Astellas Pharma US | Meals · 2025-05-06 | Izervay | $14 |
| Abbvie | Meals · 2025-03-27 | Ozurdex | $22 |
| Abbvie | Meals · 2025-03-13 | Ozurdex | $127 |
| Regeneron Healthcare Solutions | Meals · 2025-02-27 | Eylea Hd | $21 |
| Astellas Pharma Global Development | Meals · 2025-02-19 | Izervay | $117 |
| Merz Pharmaceuticals | Meals · 2025-02-08 | Xeomin | $46 |
| Regeneron Healthcare Solutions | Meals · 2025-02-07 | Eylea Hd | $120 |
| Astellas Pharma US | Meals · 2025-02-05 | Izervay | $22 |
See earlier years (2024, 2023)
2024: $1,337
| Abbvie | Ozurdex | $332 | 4 payments
|
| Astellas Pharma US | Izervay | $301 | 4 payments
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $222 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $160 | 4 payments
|
| Apellis Pharmaceuticals | Syfovre | $154 | 2 payments
|
| Genentech USA | Vabysmo | $122 | 1 payment
|
| Alcon Vision | Clareon | $25 | 1 payment
|
| Genentech | Vabysmo | $21 | 1 payment
|
2023: $371
| Coherus Biosciences | Cimerli | $112 | 1 payment
|
| AbbVie | Ozurdex | $109 | 4 payments
|
| Alimera Sciences | Iluvien | $53 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $30 | 1 payment
|
| Astellas Pharma US | None | $25 | 1 payment
|
| Bausch & Lomb Americas | Xipere | $25 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $18 | 1 payment
|
Professional record
- NPI
- 1962963769
- Licence
- CA 20A20765
- Group
- Serve the People, Inc. · Retina Macula Institute
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 4589 Via Marisol Unit 358, Los Angeles, CA, 90042
- NPI first listed
- 2019-03-26
- NPI last updated
- 2023-10-09
- NPI record certified
- 2023-05-09
This is when the NPI record was last certified, not a medical board exam.